These positive consistent data allows us suppose that our developed SKOV3 CD117+CD44+CSC vaccine induced anti-ovarian cancer efficacy that is related with the diminution of CD117+CD44+CSC as well as ALDH-positive cell populations by eliciting effective immunity in the athymic nude mouse model. Here, CD44 is linked to ovarian cancer.